Endemic-level Demand for mRNA COVID-19 Vaccine

BioNTech SE today reported financial results for the first three months of 2024, and provided an update on its corporate progress.

Total revenues reported were €187.6 million for the three months in 2024, compared to €1,277 million for the comparative period in 2023.

The Germany-based company stated the year-over-year change was mainly due to lower commercial revenues from the sales of BioNTech’s COVID-19 vaccine worldwide, resulting from endemic-level demand for COVID-19 vaccines.

“In the past weeks, we have reported positive preliminary data for our individualized and off-the-shelf mRNA-based candidates, which further underline the potential of our iNeST and FixVac platforms. We look forward to providing more updates this year across our oncology portfolio, including our bispecific antibody and ADC programs,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech, in a press release on May 6, 2024.

“In the remainder of the year, we plan to develop and commercialize a variant-adapted COVID-19 vaccine and accelerate our clinical development activities towards realizing the full potential of our oncology pipeline with a view to becoming a commercial company with marketed medicines for cancer and infectious diseases.”

BioNTech and Pfizer developed, manufactured, and delivered their Omicron XBB.1.5-adapted monovalent Comirnaty COVID-19 vaccine, which has received multiple regulatory approvals, including full approvals, authorizations for emergency or temporary use, or marketing authorizations, in more than 40 countries and regions.

BioNTech says it is now focused on preparing for variant strain vaccine adaptation to be ready for commercial launch ahead of the upcoming 2024/2025 vaccination season, pending approvals.